Stableford Capital II’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.51M Sell
7,098
-405
-5% -$414K 2.95% 8
2026
Q1
$6.9M Buy
7,503
+53
+0.7% +$53.7K 2.56% 10
2025
Q4
$8.01M Sell
7,450
-89
-1% -$85.1K 2.89% 5
2025
Q3
$5.75M Buy
7,539
+215
+3% +$160K 2.08% 11
2025
Q2
$5.95M Buy
7,324
+2
+0% +$1.55K 2.24% 10
2025
Q1
$6.15M Buy
7,322
+94
+1% +$78.2K 2.6% 11
2024
Q4
$5.58M Sell
7,228
-2,600
-26% -$2.15M 2.21% 9
2024
Q3
$9.16M Buy
9,828
+358
+4% +$322K 3.66% 3
2024
Q2
$8.58M Sell
9,470
-158
-2% -$126K 3.37% 8
2024
Q1
$7.49M Buy
9,628
+635
+7% +$452K 3.01% 10
2023
Q4
$5.72M Sell
8,993
-148
-2% -$86.4K 2.45% 10
2023
Q3
$5.19M Sell
9,141
-4,028
-31% -$2.08M 2.39% 9
2023
Q2
$6.87M Buy
+13,169
New +$5.52M 3.04% 7
2023
Q1
Sell
-13,491
Closed -$4.72M 118
2022
Q4
$4.72M Sell
13,491
-154
-1% -$54.6K 2.56% 12
2022
Q3
$4.65M Sell
13,645
-26
-0.2% -$8.24K 2.25% 14
2022
Q2
$4.12M Sell
13,671
-531
-4% -$159K 1.91% 17
2022
Q1
$4.38M Sell
14,202
-349
-2% -$89.8K 1.85% 14
2021
Q4
$3.5M Buy
14,551
+1,280
+10% +$324K 1.47% 19
2021
Q3
$3.14M Buy
13,271
+2,062
+18% +$509K 1.59% 16
2021
Q2
$2.57M Hold
11,209
1.23% 21
2021
Q1
$2.09M Hold
11,209
1.06% 27
2020
Q4
$1.89M Hold
11,209
1.11% 25
2020
Q3
$1.66M Hold
11,209
1.13% 27
2020
Q2
$1.84M Hold
11,209
1.38% 20
2020
Q1
$1.55M Hold
11,209
1.07% 30
2019
Q4
$1.47M Hold
11,209
1.34% 26
2019
Q3
$1.25M Hold
11,209
1.18% 20
2019
Q2
$1.24M Hold
11,209
1.21% 20
2019
Q1
$1.45M Sell
11,209
-2
-0% -$243 1.21% 18
2018
Q4
$1.3M Hold
11,211
1.38% 22
2018
Q3
$1.2M Hold
11,211
0.79% 35
2018
Q2
$957K Hold
11,211
0.62% 35
2018
Q1
$867K Sell
11,211
-13,298
-54% -$1.07M 0.61% 37
2017
Q4
$2.07M Buy
24,509
+1,128
+5% +$96K 1.39% 20
2017
Q3
$2M Buy
23,381
+369
+2% +$30.3K 1.45% 18
2017
Q2
$1.89M Sell
23,012
-6
-0% -$490 1.52% 18
2017
Q1
$1.94M Buy
23,018
+11,110
+93% +$890K 1.68% 20
2016
Q4
$876K Buy
+11,908
New +$887K 1.12% 28

Other funds holding LLY

Stableford Capital II's LLY Position: Q2 2026 in Review

Stableford Capital II reduced its Eli Lilly (LLY) stake by 5.4% in Q2 2026, selling an estimated $414K and leaving 7,098 shares worth $8.51M. The position accounts for 2.95% of the portfolio, ranked #8.

Stableford Capital II first reported a position in LLY in Q4 2016 and has held it in 38 quarters since. The position peaked at $9.16M in Q3 2024. 1,233 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Stableford Capital II held 7,098 shares of Eli Lilly worth $8.51M as of Q2 2026.
  • Stableford Capital II sold 405 Eli Lilly shares in Q2 2026, an estimated $414K.
  • Eli Lilly made up 2.95% of Stableford Capital II's portfolio in Q2 2026, its #8 holding.
  • Stableford Capital II first reported a position in Eli Lilly in Q4 2016 and has held it in 38 quarters since.
  • Stableford Capital II's Eli Lilly position peaked at $9.16M in Q3 2024.
  • 1,233 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Stableford Capital II's 13F filing for Q2 2026, filed 6 Jul 2026.